Pub Date : 2026-01-01Epub Date: 2026-01-07DOI: 10.1016/j.medcli.2025.107244
Halil Kazanasmaz, Fırat Gündoğmuş, Ender Can Eroğlu, Mukaddes Kalyoncu
Purpose
This study aimed to assess the diagnostic value of serum amyloid A (SAA) levels during attacks of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome.
Methods
A retrospective analysis was conducted on the medical records of 51 children diagnosed with PFAPA and 51 control patients. Serum levels of SAA, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and the neutrophil-to-lymphocyte ratio (NLR) were measured.
Results
The median SAA levels were significantly higher in the PFAPA group than in controls (p < 0.05). ROC analysis revealed that SAA had a sensitivity of 100% and a specificity of 96.1% at a cutoff value of ≥12.43 mg/L, outperforming CRP and ESR in diagnostic accuracy. While CRP and ESR had high sensitivities (90.2% and 90%, respectively), their specificities were lower (96% and 58.8%, respectively). Moreover, the high positive predictive value of SAA underscores its potential role as a reliable marker for the differential diagnosis of PFAPA.
Conclusion
SAA is a highly sensitive and specific marker for PFAPA attack, showing greater diagnostic accuracy compared to CRP and ESR. These findings suggest that SAA can serve as a valuable biomarker in the differential diagnosis of PFAPA.
{"title":"Serum amyloid A as predictive factor in PFAPA syndrome attack","authors":"Halil Kazanasmaz, Fırat Gündoğmuş, Ender Can Eroğlu, Mukaddes Kalyoncu","doi":"10.1016/j.medcli.2025.107244","DOIUrl":"10.1016/j.medcli.2025.107244","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aimed to assess the diagnostic value of serum amyloid A (SAA) levels during attacks of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted on the medical records of 51 children diagnosed with PFAPA and 51 control patients. Serum levels of SAA, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and the neutrophil-to-lymphocyte ratio (NLR) were measured.</div></div><div><h3>Results</h3><div>The median SAA levels were significantly higher in the PFAPA group than in controls (<em>p</em> <!--><<!--> <!-->0.05). ROC analysis revealed that SAA had a sensitivity of 100% and a specificity of 96.1% at a cutoff value of ≥12.43<!--> <!-->mg/L, outperforming CRP and ESR in diagnostic accuracy. While CRP and ESR had high sensitivities (90.2% and 90%, respectively), their specificities were lower (96% and 58.8%, respectively). Moreover, the high positive predictive value of SAA underscores its potential role as a reliable marker for the differential diagnosis of PFAPA.</div></div><div><h3>Conclusion</h3><div>SAA is a highly sensitive and specific marker for PFAPA attack, showing greater diagnostic accuracy compared to CRP and ESR. These findings suggest that SAA can serve as a valuable biomarker in the differential diagnosis of PFAPA.</div></div>","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"166 1","pages":"Article 107244"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2026-01-07DOI: 10.1016/j.medcli.2025.107235
Antonio Bustos-Merlo, Antonio Rosales-Castillo
{"title":"Osteopetrosis autosómica dominante tipo II asociada a CLCN7. Análisis de cinco casos","authors":"Antonio Bustos-Merlo, Antonio Rosales-Castillo","doi":"10.1016/j.medcli.2025.107235","DOIUrl":"10.1016/j.medcli.2025.107235","url":null,"abstract":"","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"166 1","pages":"Article 107235"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2026-01-07DOI: 10.1016/j.medcli.2025.107251
Thais Lizondo López , Belén López García , Neus Basté , Isabel Vilaseca , Juan José Grau , Esther Carcelero San Martín
Introduction
Recurrent respiratory papillomatosis is a rare benign airway disease caused by human papillomavirus, typically types 6 and 11. Management is often difficult due to high recurrence rates and lack of effective pharmacologic options. Recent studies suggest that EGFR and COX-2 pathways play a role in the pathogenesis of human papillomavirus-related lesions.
Patients and methods
We present an observational retrospective study of three patients with PCR confirmed human papillomavirus DNA associated to recurrent respiratory papillomatosis treated with erlotinib and celecoxib at a tertiary hospital between 2017 and 2024. Inclusion criteria were histological diagnosis, prior failure to conventional therapies, and complete clinical follow-up.
Results
Two patients exhibited sustained improvement in symptoms and lesion burden, with no significant adverse events. In one case, treatment was well tolerated over six years. A third patient discontinued therapy due to disease progression, treated with immunotherapy afterwards.
Conclusion
Combined EGFR and COX-2 inhibition may be a promising treatment strategy for recurrent respiratory papillomatosis refractory to standard therapy. These preliminary observations support further prospective investigation in selected patients.
{"title":"Recurrent respiratory papillomatosis treated with combined erlotinib and celecoxib: A retrospective study","authors":"Thais Lizondo López , Belén López García , Neus Basté , Isabel Vilaseca , Juan José Grau , Esther Carcelero San Martín","doi":"10.1016/j.medcli.2025.107251","DOIUrl":"10.1016/j.medcli.2025.107251","url":null,"abstract":"<div><h3>Introduction</h3><div>Recurrent respiratory papillomatosis is a rare benign airway disease caused by human papillomavirus, typically types 6 and 11. Management is often difficult due to high recurrence rates and lack of effective pharmacologic options. Recent studies suggest that EGFR and COX-2 pathways play a role in the pathogenesis of human papillomavirus-related lesions.</div></div><div><h3>Patients and methods</h3><div>We present an observational retrospective study of three patients with PCR confirmed human papillomavirus DNA associated to recurrent respiratory papillomatosis treated with erlotinib and celecoxib at a tertiary hospital between 2017 and 2024. Inclusion criteria were histological diagnosis, prior failure to conventional therapies, and complete clinical follow-up.</div></div><div><h3>Results</h3><div>Two patients exhibited sustained improvement in symptoms and lesion burden, with no significant adverse events. In one case, treatment was well tolerated over six years. A third patient discontinued therapy due to disease progression, treated with immunotherapy afterwards.</div></div><div><h3>Conclusion</h3><div>Combined EGFR and COX-2 inhibition may be a promising treatment strategy for recurrent respiratory papillomatosis refractory to standard therapy. These preliminary observations support further prospective investigation in selected patients.</div></div>","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"166 1","pages":"Article 107251"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145934227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2026-01-07DOI: 10.1016/j.medcli.2025.107231
Ana Victoria García , Elsa Villa-Fernández , Jessica Ares-Blanco , Alicia Cobo Irusta , Miguel García-Villarino , Tomás González-Vidal , Edelmiro Menéndez Torre , Elías Delgado , Pedro Pujante , Carmen Lambert
Aims
Automated insulin delivery (AID) systems have been developed to achieve optimal glycaemic targets to prevent or slow the progression of type 1 diabetes (T1DM) and its complications. The aim of this study is to analyse the glycemic and inflammatory profile in people with T1DM after one year of using an AID system.
Materials and methods
A longitudinal study was performed, including 33 patients who started their treatment with an AID system (Medtronic 780G – 19%, Tandem Control-IQ – 27% and Roche-Diabeloop – 54%). A biochemical analysis was performed, and a blood sample was collected prior to pump implantation and at 3, 6, and 12 months.
Results
A significant increase in time in range was observed from the first month, with significant differences always relative to baseline (p < 0.001). The coefficient of variation was significantly reduced from implantation and this reduction was maintained up to one year (p = 0.002). Similarly, significant reductions in HbA1c (p < 0.001) and blood glucose levels (p = 0.001) were observed. The expression of IL6, IL1β, TNFα and VEGF was analysed in the peripheral mononuclear cells of the same cohort, observing a significant decrease in IL1β (p = 0.047), as well as a trend of decrease in the gene expression levels of the other molecules. In addition, correlations between these genes and certain biochemical parameters were observed.
Conclusions
After one year of AID system use, we observed a significant reduction in IL1β expression, independent of baseline glycaemic control. This reduction correlated with total cholesterol, HDL, and LDL levels. Moreover, individuals with poorer initial glycaemic control showed a greater decrease in IL6 levels. These findings suggest that AID use may contribute to modulating specific inflammatory markers in people with T1DM, with differential effects depending on initial metabolic status.
{"title":"Improvements in both glycaemic and inflammatory profile in people with type 1 diabetes using automated insulin delivery systems","authors":"Ana Victoria García , Elsa Villa-Fernández , Jessica Ares-Blanco , Alicia Cobo Irusta , Miguel García-Villarino , Tomás González-Vidal , Edelmiro Menéndez Torre , Elías Delgado , Pedro Pujante , Carmen Lambert","doi":"10.1016/j.medcli.2025.107231","DOIUrl":"10.1016/j.medcli.2025.107231","url":null,"abstract":"<div><h3>Aims</h3><div>Automated insulin delivery (AID) systems have been developed to achieve optimal glycaemic targets to prevent or slow the progression of type 1 diabetes (T1DM) and its complications. The aim of this study is to analyse the glycemic and inflammatory profile in people with T1DM after one year of using an AID system.</div></div><div><h3>Materials and methods</h3><div>A longitudinal study was performed, including 33 patients who started their treatment with an AID system (Medtronic 780G – 19%, Tandem Control-IQ – 27% and Roche-Diabeloop – 54%). A biochemical analysis was performed, and a blood sample was collected prior to pump implantation and at 3, 6, and 12 months.</div></div><div><h3>Results</h3><div>A significant increase in time in range was observed from the first month, with significant differences always relative to baseline (<em>p</em> <!--><<!--> <!-->0.001). The coefficient of variation was significantly reduced from implantation and this reduction was maintained up to one year (<em>p</em> <!-->=<!--> <!-->0.002). Similarly, significant reductions in HbA1c (<em>p</em> <!--><<!--> <!-->0.001) and blood glucose levels (<em>p</em> <!-->=<!--> <!-->0.001) were observed. The expression of IL6, IL1β, TNFα and VEGF was analysed in the peripheral mononuclear cells of the same cohort, observing a significant decrease in IL1β (<em>p</em> <!-->=<!--> <!-->0.047), as well as a trend of decrease in the gene expression levels of the other molecules. In addition, correlations between these genes and certain biochemical parameters were observed.</div></div><div><h3>Conclusions</h3><div>After one year of AID system use, we observed a significant reduction in IL1β expression, independent of baseline glycaemic control. This reduction correlated with total cholesterol, HDL, and LDL levels. Moreover, individuals with poorer initial glycaemic control showed a greater decrease in IL6 levels. These findings suggest that AID use may contribute to modulating specific inflammatory markers in people with T1DM, with differential effects depending on initial metabolic status.</div></div>","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"166 1","pages":"Article 107231"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145934067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2026-01-07DOI: 10.1016/j.medcli.2025.107268
Julio Lara-Riegos , Luis Alberto Chi-Cervera , Iaarah Montalvo-Gordon , Hugo Azcorra-Pérez , Julio Torres-Romero , Víctor Arana-Argáez , Mario Ramírez-Camacho , María Eugenia Icaza-Chávez
Introduction and objectives
Determining insulin resistance (IR) is essential to identify subjects at risk for non-alcoholic fatty liver disease (NAFLD). A particular area of interest is the ability to detect patients with NAFLD using non-invasive biomarkers. This study aimed to evaluate the sensitivity, specificity, and predictive value of the metabolic index for detecting NAFLD.
Materials and methods
A retrospective study was conducted in adults of both sexes eligible for inclusion were adults of both sexes aged 18 to 85 years with and without NAFLD. Liver steatosis was measured using the controlled attenuation parameter (CAP) through FibroScan®. The metabolic index was calculated using the formula: Fasting Glucose x TG/HDL-C2. The study was carried out at the Gastrointestinal and Liver Specialty Clinic in Yucatán, Mexico, between January 2014 and November 2020, using a convenience sampling method. In a total of 138 subjects (32 healthy and 106 patients with NAFLD), anthropometric measures and laboratory tests were obtained to determine levels of triglycerides (TG), glucose, total cholesterol (TC), HDL-C, LDL-C, AST, and ALT.
Results
The metabolic index showed a specificity of 90,6% (95% CI [80,5-100]), sensitivity of 64.2% (95% CI [55-73,3]), a positive predictive value of 95,8%, a negative predictive value of 43,3%, a positive likelihood ratio of 6,83, and a negative likelihood ratio of 0,40 for detecting NAFLD.
Conclusion
The metabolic index showed high specificity for detecting NAFLD and could be used in adult patients with suspected NAFLD seen in primary health care.
{"title":"Índice metabólico como marcador predictivo no invasivo de esteatosis hepática en pacientes con enfermedad del hígado graso no alcohólico","authors":"Julio Lara-Riegos , Luis Alberto Chi-Cervera , Iaarah Montalvo-Gordon , Hugo Azcorra-Pérez , Julio Torres-Romero , Víctor Arana-Argáez , Mario Ramírez-Camacho , María Eugenia Icaza-Chávez","doi":"10.1016/j.medcli.2025.107268","DOIUrl":"10.1016/j.medcli.2025.107268","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Determining insulin resistance (IR) is essential to identify subjects at risk for non-alcoholic fatty liver disease (NAFLD). A particular area of interest is the ability to detect patients with NAFLD using non-invasive biomarkers. This study aimed to evaluate the sensitivity, specificity, and predictive value of the metabolic index for detecting NAFLD.</div></div><div><h3>Materials and methods</h3><div>A retrospective study was conducted in adults of both sexes eligible for inclusion were adults of both sexes aged 18 to 85 years with and without NAFLD. Liver steatosis was measured using the controlled attenuation parameter (CAP) through FibroScan®. The metabolic index was calculated using the formula: Fasting Glucose x TG/HDL-C2. The study was carried out at the Gastrointestinal and Liver Specialty Clinic in Yucatán, Mexico, between January 2014 and November 2020, using a convenience sampling method. In a total of 138 subjects (32 healthy and 106 patients with NAFLD), anthropometric measures and laboratory tests were obtained to determine levels of triglycerides (TG), glucose, total cholesterol (TC), HDL-C, LDL-C, AST, and ALT.</div></div><div><h3>Results</h3><div>The metabolic index showed a specificity of 90,6% (95% CI [80,5-100]), sensitivity of 64.2% (95% CI [55-73,3]), a positive predictive value of 95,8%, a negative predictive value of 43,3%, a positive likelihood ratio of 6,83, and a negative likelihood ratio of 0,40 for detecting NAFLD.</div></div><div><h3>Conclusion</h3><div>The metabolic index showed high specificity for detecting NAFLD and could be used in adult patients with suspected NAFLD seen in primary health care.</div></div>","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"166 1","pages":"Article 107268"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145934060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2026-01-14DOI: 10.1016/j.medcli.2025.107329
Liang Sun , Buhe Bao , Yu-hua Zhang , Zhenhua Du
Purpose
This study aimed to identify prognostic factors and develop a predictive model for patients with organophosphate poisoning.
Methods
A retrospective analysis of 108 cases was conducted, collecting demographic, clinical, and laboratory data including age, sex, time to treatment, plasma organophosphate (OP) levels, arterial lactate (LAC), aspartate aminotransferase (AST), creatinine (Cr), and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores. Patients were categorized into survivor and non-survivor groups. Multivariate logistic regression and receiver operating characteristic (ROC) analyses were performed to identify independent prognostic factors and assess their predictive value.
Results
The overall mortality rate was 23.15%. Non-survivors had higher age, LAC, AST, Cr, and APACHE II scores, and lower AChE levels compared to survivors. Multivariate logistic regression identified age (OR: 1.12, 95% CI: 1.05–1.22) and AST (OR: 1.03, 95% CI: 1.01–1.05) as independent prognostic factors. ROC analysis validated a model combining age, AChE, and AST, showing an excellent discriminative ability with an AUC of 0.95 (95% CI: 0.91–0.99), sensitivity of 1.00, and specificity of 0.90.
Conclusions
Age and AST are significant prognostic factors for organophosphate poisoning. Combining these factors enhances predictive accuracy, aiding clinical decision-making and emphasizing early aggressive management to improve survival rates.
{"title":"Prognostic factors and predictive models for outcomes in organophosphate poisoning: A retrospective analysis","authors":"Liang Sun , Buhe Bao , Yu-hua Zhang , Zhenhua Du","doi":"10.1016/j.medcli.2025.107329","DOIUrl":"10.1016/j.medcli.2025.107329","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aimed to identify prognostic factors and develop a predictive model for patients with organophosphate poisoning.</div></div><div><h3>Methods</h3><div>A retrospective analysis of 108 cases was conducted, collecting demographic, clinical, and laboratory data including age, sex, time to treatment, plasma organophosphate (OP) levels, arterial lactate (LAC), aspartate aminotransferase (AST), creatinine (Cr), and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores. Patients were categorized into survivor and non-survivor groups. Multivariate logistic regression and receiver operating characteristic (ROC) analyses were performed to identify independent prognostic factors and assess their predictive value.</div></div><div><h3>Results</h3><div>The overall mortality rate was 23.15%. Non-survivors had higher age, LAC, AST, Cr, and APACHE II scores, and lower AChE levels compared to survivors. Multivariate logistic regression identified age (OR: 1.12, 95% CI: 1.05–1.22) and AST (OR: 1.03, 95% CI: 1.01–1.05) as independent prognostic factors. ROC analysis validated a model combining age, AChE, and AST, showing an excellent discriminative ability with an AUC of 0.95 (95% CI: 0.91–0.99), sensitivity of 1.00, and specificity of 0.90.</div></div><div><h3>Conclusions</h3><div>Age and AST are significant prognostic factors for organophosphate poisoning. Combining these factors enhances predictive accuracy, aiding clinical decision-making and emphasizing early aggressive management to improve survival rates.</div></div>","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"166 1","pages":"Article 107329"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2026-01-07DOI: 10.1016/j.medcli.2025.107280
Héctor Lago-Gancedo, Ana Cuesta-Díaz de Rada, María Balboa-Alonso
{"title":"Linfohistiocitosis hemofagocítica (LHH) familiar tipo 2, que simula un síndrome CLIPPERS","authors":"Héctor Lago-Gancedo, Ana Cuesta-Díaz de Rada, María Balboa-Alonso","doi":"10.1016/j.medcli.2025.107280","DOIUrl":"10.1016/j.medcli.2025.107280","url":null,"abstract":"","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"166 1","pages":"Article 107280"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145934077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2026-01-07DOI: 10.1016/j.medcli.2025.107264
Cristina Cremades Artacho, Inés Monge-Escartín, Esther Carcelero San Martín
{"title":"Treatment of aspergillosis in a hematologic patient with intraventricular amphotericin B","authors":"Cristina Cremades Artacho, Inés Monge-Escartín, Esther Carcelero San Martín","doi":"10.1016/j.medcli.2025.107264","DOIUrl":"10.1016/j.medcli.2025.107264","url":null,"abstract":"","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"166 1","pages":"Article 107264"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号